{"id":39187,"date":"2023-09-25T04:21:13","date_gmt":"2023-09-25T02:21:13","guid":{"rendered":"https:\/\/kapitalpartner.dk\/?p=39187"},"modified":"2023-10-02T04:22:03","modified_gmt":"2023-10-02T02:22:03","slug":"evaxion-enters-new-partnership-danish-biotech-weekly-39","status":"publish","type":"post","link":"https:\/\/kapitalpartner.dk\/en\/evaxion-enters-new-partnership-danish-biotech-weekly-39\/","title":{"rendered":"Evaxion enters new partnership: Danish Biotech Weekly (39)"},"content":{"rendered":"\n

Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc. <\/em><\/p>\n\n\n\n

In the past week, Evaxion<\/strong> Biotech entered a partnership regarding a vaccine against gonorrhea, Ascendis Pharma presented results of a trial with TransCon, and ViroGates announced positive results from a clinical trial suPAR-guided antibiotec treatment in sepsis.<\/strong><\/p>\n\n\n\n

The past week was another week full of exciting news with 8 of the 20 listed Danish biotech companies publishing news. 11 of the 20 companies had a positive share price development the past week and 8 companies have a positive share price performance year to date. Cessatech continues to be the best performing stock year-to-date.<\/strong><\/p>\n\n\n\n

\n
Register for the Danish Biotech Weekly newsletter<\/strong><\/a><\/div>\n<\/div>\n\n\n\n

<\/p>\n\n\n\n

Company news the past week<\/strong><\/p>\n\n\n\n

Ascendis Pharma<\/strong><\/p>\n\n\n\n

Ascendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon\u2122 hGH in Pediatric Growth Hormone Deficiency (Link<\/a>)<\/p>\n\n\n\n

Biosergen<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Cessatech<\/strong><\/p>\n\n\n\n

Cessatech announces last participant dosed in pivotal trial 0205 with lead candidate CT001<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

CS Medica<\/strong><\/a><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Curasight<\/strong><\/a><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Evaxion Biotech<\/strong><\/p>\n\n\n\n

Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against Gonorrhea (Link<\/a>)<\/p>\n\n\n\n

Expres2ion<\/strong><\/p>\n\n\n\n

Last day of trading in warrants of series TO 8 in Expres2ion Biotechnologies 18 September 2023 (Link<\/a>)<\/p>\n\n\n\n

Fluoguide<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Genmab<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Gubra<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Initiator Pharma<\/strong><\/p>\n\n\n\n

Initiator Pharma announces indication expansion \u2013 clinical drug candidates active in models of female sexual dysfunction<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

IO Biotech<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Pila Pharma<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Saniona<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Scandion Oncology<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

SynAct Pharma<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

ViroGates<\/strong><\/p>\n\n\n\n

ViroGates announces positive results from a randomized controlled clinical trial on suPAR-guided antibiotic treatment in sepsis presented today at the European Shock Conference in Vienna, Austria<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

Zealand Pharma<\/strong><\/p>\n\n\n\n

Zealand Pharma A\/S – admittance to trading and official listing of new shares due to exercise of employee warrants<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

Y-mAbs Therapeutics<\/strong><\/p>\n\n\n\n

Y-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric Oncology<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

2cureX<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

SELECTED CASES<\/strong><\/p>\n\n\n\n

\n
\n

Curasight<\/a><\/strong><\/h2>\n\n\n\n
\n\n\n\n
\"\"<\/a><\/figure>\n\n\n\n
\n
Investment Case<\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n
\n

CS Medica<\/a><\/strong><\/h2>\n\n\n\n
\n\n\n\n
\"\"<\/a><\/figure>\n\n\n\n
\n
Investment case<\/mark><\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n

<\/p>\n\n\n\n

\n
Interested in Nordic healthcare stocks? View our weekly Nordic newsletter here (in Danish)<\/a><\/div>\n<\/div>\n\n\n\n

<\/p>\n\n\n\n

SHARE PRICE DEVELOPMENTS<\/strong><\/p>\n\n\n\n

On average, the Danish biotech stocks delivered a positive share price performance last week of 4.8%. Biosergen rose 77% without even announcing any news. ViroGates followed with a 24% increase after announces positive results from a randomized controlled clinical trial on suPAR-guided antibiotic treatment in sepsis. Notably, Evaxion only rose 4% after expanding preclinical bacterial pipeline with a leading pharmaceutical company as well as entered a partnership to develop a vaccine against gonorrhea. On the other hand, Ascendis Pharma fell the most with a 7% decrease following results of a trial with TransCon. The best stocks year-to-date include Curasight, Cessatech Fluoguide, <\/strong>and Saniona<\/strong> after soaring 87-154%. Overall, the Danish biotech stocks are in positive terrotory this year with a year-to-date return of 3.3%<\/strong>. However, it is driven by the few companies delivering very positive returns.<\/p>\n\n\n\n

Read more about Curasight (in Danish):<\/strong><\/mark> Et succesfuldt kvartal for Curasight med mere i vente<\/a><\/p>\n\n\n\n

Overview of share price developments the past week, year-to-date and last twelve months<\/strong><\/p>\n\n\n\n

\"\"<\/figure>\n","protected":false},"excerpt":{"rendered":"

Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc. In the past week, Evaxion Biotech entered a partnership regarding a vaccine against gonorrhea, Ascendis Pharma presented results of a trial with TransCon, and […]<\/p>\n","protected":false},"author":11,"featured_media":37397,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[9],"tags":[],"class_list":["post-39187","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-en-investeringscases"],"acf":[],"yoast_head":"\nEvaxion enters new partnership: Danish Biotech Weekly (39) | Kapital Partner A\/S<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kapitalpartner.dk\/en\/evaxion-enters-new-partnership-danish-biotech-weekly-39\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evaxion enters new partnership: Danish Biotech Weekly (39) | Kapital Partner A\/S\" \/>\n<meta property=\"og:description\" content=\"Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc. In the past week, Evaxion Biotech entered a partnership regarding a vaccine against gonorrhea, Ascendis Pharma presented results of a trial with TransCon, and […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kapitalpartner.dk\/en\/evaxion-enters-new-partnership-danish-biotech-weekly-39\/\" \/>\n<meta property=\"og:site_name\" content=\"Kapital Partner A\/S\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/kapitalpartner\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-25T02:21:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-02T02:22:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1015\" \/>\n\t<meta property=\"og:image:height\" content=\"533\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Anders S\u00f8ndergaard\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:site\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Anders S\u00f8ndergaard\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/evaxion-enters-new-partnership-danish-biotech-weekly-39\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/evaxion-enters-new-partnership-danish-biotech-weekly-39\/\"},\"author\":{\"name\":\"Anders S\u00f8ndergaard\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed\"},\"headline\":\"Evaxion enters new partnership: Danish Biotech Weekly (39)\",\"datePublished\":\"2023-09-25T02:21:13+00:00\",\"dateModified\":\"2023-10-02T02:22:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/evaxion-enters-new-partnership-danish-biotech-weekly-39\/\"},\"wordCount\":566,\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/evaxion-enters-new-partnership-danish-biotech-weekly-39\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\",\"articleSection\":[\"All investment Cases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/evaxion-enters-new-partnership-danish-biotech-weekly-39\/\",\"url\":\"https:\/\/kapitalpartner.dk\/en\/evaxion-enters-new-partnership-danish-biotech-weekly-39\/\",\"name\":\"Evaxion enters new partnership: Danish Biotech Weekly (39) | Kapital Partner A\/S\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/evaxion-enters-new-partnership-danish-biotech-weekly-39\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/evaxion-enters-new-partnership-danish-biotech-weekly-39\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\",\"datePublished\":\"2023-09-25T02:21:13+00:00\",\"dateModified\":\"2023-10-02T02:22:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/evaxion-enters-new-partnership-danish-biotech-weekly-39\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/kapitalpartner.dk\/en\/evaxion-enters-new-partnership-danish-biotech-weekly-39\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/evaxion-enters-new-partnership-danish-biotech-weekly-39\/#primaryimage\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png\",\"width\":1015,\"height\":533},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/evaxion-enters-new-partnership-danish-biotech-weekly-39\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"All investment Cases\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/en-investeringscases\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Evaxion enters new partnership: Danish Biotech Weekly (39)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/kapitalpartner.dk\/#website\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"name\":\"Kapital Partner A\/S\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/kapitalpartner.dk\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\",\"name\":\"Kapital Partner A\/S\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"width\":496,\"height\":432,\"caption\":\"Kapital Partner A\/S\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/kapitalpartner\",\"https:\/\/x.com\/KapitalPartner\",\"https:\/\/www.linkedin.com\/company\/10438322\",\"https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed\",\"name\":\"Anders S\u00f8ndergaard\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g\",\"caption\":\"Anders S\u00f8ndergaard\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Evaxion enters new partnership: Danish Biotech Weekly (39) | Kapital Partner A\/S","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kapitalpartner.dk\/en\/evaxion-enters-new-partnership-danish-biotech-weekly-39\/","og_locale":"en_US","og_type":"article","og_title":"Evaxion enters new partnership: Danish Biotech Weekly (39) | Kapital Partner A\/S","og_description":"Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc. In the past week, Evaxion Biotech entered a partnership regarding a vaccine against gonorrhea, Ascendis Pharma presented results of a trial with TransCon, and […]","og_url":"https:\/\/kapitalpartner.dk\/en\/evaxion-enters-new-partnership-danish-biotech-weekly-39\/","og_site_name":"Kapital Partner A\/S","article_publisher":"https:\/\/www.facebook.com\/kapitalpartner","article_published_time":"2023-09-25T02:21:13+00:00","article_modified_time":"2023-10-02T02:22:03+00:00","og_image":[{"width":1015,"height":533,"url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","type":"image\/png"}],"author":"Anders S\u00f8ndergaard","twitter_card":"summary_large_image","twitter_creator":"@KapitalPartner","twitter_site":"@KapitalPartner","twitter_misc":{"Written by":"Anders S\u00f8ndergaard","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kapitalpartner.dk\/en\/evaxion-enters-new-partnership-danish-biotech-weekly-39\/#article","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/en\/evaxion-enters-new-partnership-danish-biotech-weekly-39\/"},"author":{"name":"Anders S\u00f8ndergaard","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed"},"headline":"Evaxion enters new partnership: Danish Biotech Weekly (39)","datePublished":"2023-09-25T02:21:13+00:00","dateModified":"2023-10-02T02:22:03+00:00","mainEntityOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/evaxion-enters-new-partnership-danish-biotech-weekly-39\/"},"wordCount":566,"publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/evaxion-enters-new-partnership-danish-biotech-weekly-39\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","articleSection":["All investment Cases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/kapitalpartner.dk\/en\/evaxion-enters-new-partnership-danish-biotech-weekly-39\/","url":"https:\/\/kapitalpartner.dk\/en\/evaxion-enters-new-partnership-danish-biotech-weekly-39\/","name":"Evaxion enters new partnership: Danish Biotech Weekly (39) | Kapital Partner A\/S","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/evaxion-enters-new-partnership-danish-biotech-weekly-39\/#primaryimage"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/evaxion-enters-new-partnership-danish-biotech-weekly-39\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","datePublished":"2023-09-25T02:21:13+00:00","dateModified":"2023-10-02T02:22:03+00:00","breadcrumb":{"@id":"https:\/\/kapitalpartner.dk\/en\/evaxion-enters-new-partnership-danish-biotech-weekly-39\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kapitalpartner.dk\/en\/evaxion-enters-new-partnership-danish-biotech-weekly-39\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/en\/evaxion-enters-new-partnership-danish-biotech-weekly-39\/#primaryimage","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/03\/Danish-Biotech-Weekly.png","width":1015,"height":533},{"@type":"BreadcrumbList","@id":"https:\/\/kapitalpartner.dk\/en\/evaxion-enters-new-partnership-danish-biotech-weekly-39\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kapitalpartner.dk\/en\/"},{"@type":"ListItem","position":2,"name":"All investment Cases","item":"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/en-investeringscases\/"},{"@type":"ListItem","position":3,"name":"Evaxion enters new partnership: Danish Biotech Weekly (39)"}]},{"@type":"WebSite","@id":"https:\/\/kapitalpartner.dk\/#website","url":"https:\/\/kapitalpartner.dk\/","name":"Kapital Partner A\/S","description":"","publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kapitalpartner.dk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/kapitalpartner.dk\/#organization","name":"Kapital Partner A\/S","url":"https:\/\/kapitalpartner.dk\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","width":496,"height":432,"caption":"Kapital Partner A\/S"},"image":{"@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/kapitalpartner","https:\/\/x.com\/KapitalPartner","https:\/\/www.linkedin.com\/company\/10438322","https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w"]},{"@type":"Person","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed","name":"Anders S\u00f8ndergaard","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g","caption":"Anders S\u00f8ndergaard"}}]}},"_links":{"self":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/39187"}],"collection":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/comments?post=39187"}],"version-history":[{"count":1,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/39187\/revisions"}],"predecessor-version":[{"id":39190,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/39187\/revisions\/39190"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media\/37397"}],"wp:attachment":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media?parent=39187"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/categories?post=39187"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/tags?post=39187"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}